FDA Issues Final Guidance on Postapproval Pregnancy Safety Studies for Drugs and Biologics

Regulatory affairs leads and pharmacovigilance teams at drug and biologics manufacturers now have a defined methodological framework to follow: the FDA has issued its final guidance, Postapproval Pregnancy Safety Studies, establishing recommendations for how sponsors should design and conduct safety studies in pregnant populations after approval. The document carries direct implications for postmarket surveillance planning, labeling update timelines, and real-world evidence strategies.

The guidance addresses a persistent gap in the approval pathway. At the time many drugs and biologics receive FDA approval, human pregnancy safety data is limited or absent, because pregnant individuals are routinely excluded from pre-approval clinical trials. The agency's position is that collecting this data postapproval is not optional context but a structured obligation tied to labeling accuracy and patient counseling.

Three methodological approaches are outlined: pregnancy registries, complementary studies drawing on real-world data, and descriptive studies built from individual case reports. The guidance recommends using these methods in combination rather than in isolation, and explicitly calls for alignment with best practices for observational research, given that randomized designs are rarely feasible in this population. Sponsors are also directed to cross-reference existing FDA guidances on study design, pharmacovigilance, and postmarket requirements.

Multidisciplinary input is flagged as a design requirement. The agency notes that these studies typically require expertise spanning obstetrics, pediatrics, genetics, and statistics, a consideration that affects both internal resourcing decisions and the scope of any contract research arrangements sponsors may need to establish.

Acting CDER Director Tracy Beth Hoeg, M.D., Ph.D., noted that post-marketing data, when properly structured, can allow pregnancy-related risks to be identified more promptly and incorporated into labeling in a clinically useful form. That framing positions the guidance less as a compliance burden and more as a mechanism for closing a known evidence deficit that currently limits prescriber confidence.

As with all FDA guidances, the document reflects the agency's current thinking and does not create legally enforceable requirements under 21 CFR; however, sponsors deviating from the recommended approaches would be expected to justify alternative methodologies during regulatory interactions and inspections.

Pharmacovigilance and regulatory teams should assess existing postmarket commitments and study protocols against the new framework, particularly where pregnancy exposure data is currently collected through registries alone without complementary real-world data components.

Source: FDA Press Releases RSS Feed via fda.gov, May 8, 2026.